Analyst Research and Recommendations: Incyte Corporation (INCY), Merck & Co., Inc. (MRK)
- Author: Zachary Reyes Feb 28, 2017,
Feb 28, 2017, 4:57
The stock gained 7.59% in total of its share price.
Many research firms have provided their ratings on Incyte Corporation (NASDAQ:INCY) where Credit Suisse provided Outperform rating on the stock on 23-Jan-17. Incyte Corporation P/E (price to earnings) ratio is 243.88 and Forward P/E ratio of 120.27. Finally, Goldman Sachs Group, Inc. BMO Capital Markets reaffirmed an "outperform" rating and set a $126.00 target price (up previously from $121.00) on shares of Incyte Corporation in a research note on Saturday, November 19th. Analysts have a mean recommendation of 2.20 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).
In case of Revenue Estimates, 12 analysts have provided their consensus Average Revenue Estimates for Incyte Corporation as 377.92 Million.
On Dec 16 Incyte Corporation (NASDAQ:INCY) reported its EPS in the last quarter as $0.05/Share lagging the analyst estimate of $0.13/Share by the difference of $-0.08. The technical rating goes from one, the weakest upside technical, to five, the highest upside technical and focuses on the real-time stock price relative to various moving averages as well as moving averages relative to each other. The high end target price has shares touching $141 and the low end target estimate has the stock moving to $92 within the year. The company had revenue of $326.50 million for the quarter, compared to analysts expectations of $327.14 million. It has returns on equity of -14.90%, which is measuring a corporation's profitability by revealing how much profit generates by ACHN with the shareholders' money.
Incyte Corporation (NASDAQ:INCY), stock is trading $125.49 above the 52-week high and has displayed a high EPS growth of 18.70% in last 5 years. During the same period in the prior year, the company earned $0.29 earnings per share. For the Current Quarter, 12 analysts are projecting the mean EPS to be $0.62/share.
In related news, EVP Reid M. Huber sold 11,739 shares of the firm's stock in a transaction dated Monday, January 9th. The median estimate represents a 4.41% increase from the last price of 131.21. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The company's institutional ownership is monitored at 95.6 percent.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Fred Alger Management Inc. raised its stake in Incyte Corporation by 228.6% in the fourth quarter. The firm's quarterly revenue was up 33.9% on a year-over-year basis. Capital International Investors now owns 5,918,033 shares of the biopharmaceutical company's stock valued at $473,324,000 after buying an additional 499,536 shares during the period. Fifth Third Bancorp now owns 1,678 shares of the biopharmaceutical company's stock worth $134,000 after buying an additional 234 shares in the last quarter. The target implies a 4.82% spike from where the shares are now trading. Sumitomo Mitsui Asset Management Company LTD now owns 11,453 shares of the biopharmaceutical company's stock valued at $916,000 after buying an additional 97 shares in the last quarter.
Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics.